反応式
[F:1][C:2]1[CH:3]=[C:4]([N:9]2[C:18](=[O:19])[C:17]3[C:12](=[CH:13][CH:14]=[CH:15][CH:16]=3)[N:11]=[C:10]2[CH:20]([NH:22][C:23]2[N:31]=[CH:30][N:29]=[C:28]3[C:24]=2[N:25]=[CH:26][NH:27]3)[CH3:21])[CH:5]=[C:6]([F:8])[CH:7]=1.[NH2:32]C1N=C2C(NC=N2)=C(Br)N=1.BrC1N=CN=C2C=1NC=N2.BrC1C2C(NC(C3N(C4C=CC=C(F)C=4)C(=O)C4C(=CC=CC=4C)N=3)C)=NC=NC=2NC=1>>[NH2:32][C:30]1[N:29]=[C:28]2[C:24]([N:25]=[CH:26][NH:27]2)=[C:23]([NH:22][CH:20]([C:10]2[N:9]([C:4]3[CH:3]=[C:2]([F:1])[CH:7]=[C:6]([F:8])[CH:5]=3)[C:18](=[O:19])[C:17]3[C:12](=[CH:13][CH:14]=[CH:15][CH:16]=3)[N:11]=2)[CH3:21])[N:31]=1参加物
5
実験手順
Compound 99 was prepared using the general procedure described above with respect to compound 95, but 2-amino-6-bromopurine was substituted for 6-bromopurine in step D. ESI-MS m/z 435 (MH+). Compound 96 is shown below.
出典と根拠
- ORDレコード
- ord-5e3850ab85c848eb9f304bbc6b4e7f66
- 出典データセット
- uspto-grants-2012_06
- 特許番号
- US08207153B2
関連ノート
読み込み中…